Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(SAU: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Blog posts about
 
Pharma’s Huge Threat (and Opportunity): mRx
June 23, 2012
It was only a matter of time before healthcare providers would start prescribing mHealth apps as soon as they proved to be as or more effective than prescription drugs. Happtique, a mobile health... Read More
category mHealth , patient relationship management , Health , and 19 more.
from TechCrunch
Index Launches Its First Life Sciences Fund: $200M And Partnering With Glaxo and Johnson & Johnson
March 21, 2012
Index Ventures may be best known on these pages for its technology investments, but today it launched a new fund that points to how the company is willing to put its money into other examples of strong... Read More
category TC , Life Sciences , Venture Capital , and 3 more.
from TechCrunch
Dumb Employers, Lucky Startups And An Untapped Reservoir
March 19, 2012
A group of women is re-entering the workforce today and reshaping how products are made across key tech sectors like health & wellness, commerce and social products. Not only do they have the... Read More
category Microsoft , Brad Feld , Group Health , and 21 more.
from TechCrunch
What Pharma Can Learn From the Railroads and IBM
February 26, 2012
Pharmaceutical companies are in trouble with ongoing patent cliffs with a clear choice facing them. They can follow the path of the railroad industry which is the path most are on right now.... Read More
category Data General , DEC , Health , and 16 more.
from TechCrunch
Bristol-Myers Squibb asked to cure high drug costs…
March 22, 2011
It’s still high season for proxies, which means we’re spending a lot of time wading through pages filled with discussions about executive compensation, board members’ qualifications to serve, the... Read More
category proxy , Shareholder proposals , pharmaceutical
from footnoted*
Five High Profile Health Care Companies Valuations with Warnings
February 27, 2011
The selection of top five drug / pharmaceutical companies are based on the following supportive data. It includes their short and longer-term price, and earnings projected price performance. Other than... Read More
category Short , Cycle Analysis and Inflection Points , Financial economics , and 24 more.
from CEOWORLD Magazine
APEIRON ACQUIRES RIGHTS FOR A PHASE II BIOLOGIC AGAINST NEUROBLASTOMA AND OTHER CANCERS FROM MERCK KGAA, GERMANY
February 01, 2011
Vienna-based biotech company Apeiron Biologics AG strengthens its cancer immunotherapy portfolio by acquiring rights to further develop and commercialize the immunocytokine hu14.18-IL2 from Merck KGaA,... Read More
category then lead product , Pharmacology , melanoma , and 32 more.
from CEOWORLD Magazine
Vision China- GlaxoSmithKline to buy Nanjing MeiRui Pharma Co. for $70m
December 07, 2010
GlaxoSmithKline PLC (GSK), anglo-American drugs giant, has entered into an agreement to acquire Chinese urology and allergy treatments specialist Nanjing MeiRui Pharma Co., Ltd for around $70 million.... Read More
category treatment for benign prostatic hyperplasia , overactive bladder syndrome , pharmaceutical , and 33 more.
from CEOWORLD Magazine
Finally Japan’s Otsuka Holdings Sets Price for $2.4 Billion largest health-care Tokyo IPO
December 06, 2010
Japan’s Otsuka Holdings priced shares in its $2.4 billion initial public offering (IPO), 2nd-biggest Japan IPO this year after Dai-ichi Life, at the lower end of its range, reflecting investors’... Read More
category Otsuka Holdings IPO , Otsuka Holdings , Financial economics , and 27 more.
from CEOWORLD Magazine
Genzyme considering contingent value right (CVR) deal structure to help deadlock with Sanofi-Aventis
November 21, 2010
Genzyme Corp. (GENZ), U.S. biotechnology firm, is exploring a new deal structure that might help break $18.5 billion hostile takeover bid deadlock with French drugmaker Sanofi-Aventis SA (SASY), as it... Read More
category Genzyme Corp/ , Sanofi/Aventis , Oklahoma City , and 21 more.
from CEOWORLD Magazine
Eisai Co Ltd’s breast cancer drug Halaven (eribulin mesylate) approved by U.S. Food and Drug Administration
November 15, 2010
Eisai Co Ltd’s (4523.TO, ESALY) new breast cancer drug, Halaven (eribulin mesylate), has been approved as a treatment for metastatic breast-cancer patients who have received at least two prior... Read More
category National Cancer Institute , metastatic breast cancer , Ixabepilone , and 28 more.
from CEOWORLD Magazine
Spanish Grifols improves Talecris Biotherapeutics Holdings Corp bid
November 11, 2010
Spanish pharmaceutical firm Grifols SA (GRLS.MC), Europe’s largest maker of blood-plasma products, has bowed to a class-action suit filed by some shareholders of its bid target Triangle-based Talecris... Read More
category Europe , blood/plasma products , Grifols , and 17 more.
from CEOWORLD Magazine
Sanofi Aventis CEO Chris Viehbacher Insists Genzyme Deal at a reasonable price
September 15, 2010
French drugmaker Sanofi Aventis SA (SASY), world’s fourth-biggest pharmaceutical company, Chief Executive Officer Chris Viehbacher sees a reasonable chance of buying Genzyme (GENZ) at a fair price, but... Read More
category Pharmacology , USD , pharmaceutical , and 31 more.
from CEOWORLD Magazine
Johnson and Johnson – Valuation Compression has Created a Good Entry Point
February 23, 2010
Johnson & Johnson (JNJ, news: 63.49 -0.32 -0.50%, cap: 175.2B, 1yr target: 71.18) is likely the world’s largest and most diverse health-care company. They operate c three divisions: Pharmaceutical,... Read More
category johnson and johnson , JNJ , Consumer , and 8 more.
from CEOWORLD Magazine
German drug and chemical maker Merck KGaA net income falls
October 26, 2009
var fbShare = {url: 'http://ceoworld.biz/ceo/2009/10/26/german-drug-and-chemical-maker-merck-kgaa-net-income-falls/',size:'large'}German pharmaceutical and chemical company Merck KGaA (MRCG.DE) said... Read More
category Tech and Web , Sharp Corp , Merck , and 7 more.
from CEOWORLD Magazine
Ranbaxy Laboratories a unit of Japan’s Daiichi Sankyo Posts Profit, cost efficiency a reason CEO Atul Sobti says
October 26, 2009
var fbShare = {url: 'http://ceoworld.biz/ceo/2009/10/26/ranbaxy-laboratories-a-unit-of-japans-daiichi-sankyo-posts-profit-cost-efficiency-a-reason-ceo-atul-sobti-says/',size:'large'}Ranbaxy... Read More
category Tech and Web , Ranbaxy , Ranbaxy Laboratories , and 2 more.
from CEOWORLD Magazine
Onyx Pharmaceuticals to acquire private biopharmaceutical firm Proteolix Inc for $276 million
October 13, 2009
Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) (ONXX.O) has agreed to buy Proteolix Inc. for $276 million in cash. Proteolix is focused on discovering and developing novel therapies that target the... Read More
category Tech and Web , myeloma , proteasome , and 9 more.
from CEOWORLD Magazine
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here